

Cystic Fibrosis Agents, Oral - Washington Prior Authorization Request Form

Please complete this <u>entire</u> form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form may contain multiple pages. Please complete all pages to avoid a delay in our decision. Allow at least 24 hours for review.

Section A – Member Inforn	nation				T			
First Name:		Last Name		Member ID:				
Address:								
City:	State:			ZIP Code:				
Phone:	DOB:			Allergies:				
Primary Insurance Information (if any):								
Is the requested medication: New or Continuation of Therapy? If continuation, list start date: 								
Is this patient currently he	ospitalized?	Yes 🗆 No	If recently	discharged, list disc	harge dat	:e:		
Section B - Provider Inforr	nation							
First Name:			Last Name:	State:	T	M.D./D.O.		
Address:				City:			ZIP code:	
Phone:	Fax:		NPI #:	Specialty:	Specialty:			
Office Contact Name / Fax atte	ention to:							
Section C - Medical Inform	ation				0			
Medication: Strength:								
Directions for use: Quantity:								
Diagnosis (Please be specific & provide as much information as possible): ICD-10 CODE:							DE:	
Is this member pregnant? Yes No If yes, what is this member's due date?								
Section D – Previous Medi	cation Trials					Beesen	for foilure /	
Medication Name	Strength	Dire	ections	Dates of Therap	у	Reason for failure / discontinuation		
Section E – Additional info						neet the	patient's needs:	
	Please refer to	the patien	t's PDL for a	a list of preferred alte	rnatives			



Cystic Fibrosis Agents, Oral - Washington Prior Authorization Request Form

Member First name:

Member Last name:

Member DOB:

Clinical and Drug Specific Information

ALL REQUESTS:

- Does the patient have a diagnosis of cystic fibrosis? $\hfill\square$ Yes $\hfill\square$ No

- Has the patient demonstrated failure or intolerance to a majority of the preferred oral Cystic Fibrosis agents? □ Yes □ No

(If yes, complete Section D above with medication information, including dose, date of trial, and reason for discontinuation)

- Does the patient have confirmation of 2 copies of the F508del mutation in the CFTR gene (i.e. the patient is homozygous for the F508del mutation)?
 Que Yes
 Que No
- Does the patient have documentation of at least ONE mutation in the CFTR gene that is responsive to the requested medication potentiation?
 □ Yes □ No

A1067T	G1244E	R352Q		
c.3199G>A	c.3731G>A	c.1055G>A		
A455E	G1349D			
c.1364C>A	c.4046G>A	c.220C>T		
D110E	G178R	S1251N		
c.330C>A	c.532G>A	c.3752G>A		
D110H	G551D	S1255P		
c.328G>C	c.1652G>A	c.3763T>C		
D1152H	G551S	S549N		
c.3454G>C	c.1651G>A	c.1646G>A		
D1270N	K1060T	S549R		
c.3808G>A	c.3179A>C	c.1645A>C,		
C.58080-A	C.31/3A-C	c.1647T>G		
D579G	L206W	S945L		
c.1736A>G	c.617T>G	c.2834C>T		
E193K	P67L	S977F		
c.577G>A	c.200C>T	c.2930C>T		
E56K	R1070Q	2789+5G→A		
c.166G>A	c.3209G>A	c.2657+5G>A		
E831X	<i>R1070W</i>	3272 - 26A→G		
c.2491G>T	c.3208C>T	c.3140-26A>G		
F1052V	<i>R117C</i>	3849+10kbC→T		
c.3154T>G	c.349C>T	c.3718-2477C>T		
F1074L	R117H	$711+3A \rightarrow G$		
c.3222T>A	c.350G>A	c.579+3A>G		
G1069R	R347H	F508del/F508del		
c.3205G>A	c.1040G>A	c.1521_1523delCTT		

Requests for CONTINUATION OF THERAPY:

- Does the patient meet one of the following:
□ Yes
□ No (check which applies)

 \Box FEV₁ has significantly improved from baseline

□ Stabilization of disease

Provider Signature: _____

Date:

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.